| |
| |
|
| Insider
Information: |
Ahmed Nadim |
| Relationship: |
EVP and President, Hem... |
| City: |
Summit |
| State: |
NJ |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
38,889 |
|
|
Indirect Shares
|
1,966 |
|
|
| Direct
Value |
$1,744,172 |
|
|
|
Indirect Value
|
$88,175 |
|
|
| Total
Shares |
40,855 |
|
|
| Total
Value |
$1,832,347 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
|
Bristol-Myers Squibb Co |
BMY |
EVP and President, Hem... |
2020-12-31 |
38,889 |
2020-12-31 |
1,966 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
23 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMY |
Bristol-Myers Squibb Co |
EVP and President, Hematology |
• – – |
2020-12-31 |
4 |
D |
$62.03 |
$475,150 |
D/D |
(7,660) |
38,889 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP and President, Hematology |
• – – |
2020-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,946 |
46,549 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP and President, Hematology |
• – – |
2020-12-02 |
4 |
D |
$62.18 |
$210,168 |
D/D |
(3,380) |
31,603 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP and President, Hematology |
• – – |
2020-12-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,594 |
34,983 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP and President, Hematology |
• – – |
2020-10-30 |
4 |
D |
$58.45 |
$133,909 |
D/D |
(2,291) |
28,389 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP and President, Hematology |
• – – |
2020-10-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,650 |
30,680 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP and President, Hematology |
• – – |
2020-05-01 |
4 |
D |
$60.26 |
$86,353 |
D/D |
(1,433) |
26,030 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
EVP and President, Hematology |
• – – |
2020-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,908 |
27,463 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
President, Hematology |
• – – |
2020-03-01 |
4 |
D |
$59.06 |
$500,415 |
D/D |
(8,473) |
24,555 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
President, Hematology |
• – – |
2020-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,204 |
33,028 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
President, Hematology |
• – – |
2020-02-04 |
4 |
D |
$64.29 |
$68,855 |
D/D |
(1,071) |
15,824 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
President, Hematology |
• – – |
2020-02-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,076 |
16,895 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., GLOBAL HEM. AND ONC. |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
25,875 |
40,694 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., GLOBAL HEM. AND ONC. |
• – – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(40,694) |
0 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., GLOBAL HEM. AND ONC. |
• – – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,966) |
0 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
President, Hematology |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
D/D |
14,819 |
14,819 |
0 |
- |
|
| BMY |
Bristol-Myers Squibb Co |
President, Hematology |
• – – |
2019-11-20 |
4 |
A |
$0.00 |
$0 |
I/I |
1,966 |
1,966 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., GLOBAL HEM. AND ONC. |
• – – |
2019-10-31 |
4 |
D |
$108.03 |
$118,401 |
D/D |
(1,096) |
14,819 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., GLOBAL HEM. AND ONC. |
• – – |
2019-10-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,281 |
15,915 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., HEMATOLOGY AND ONCOLOGY |
• – – |
2019-05-02 |
4 |
D |
$95.21 |
$46,653 |
D/D |
(490) |
12,634 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., HEMATOLOGY AND ONCOLOGY |
• – – |
2019-05-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,563 |
13,124 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., HEMATOLOGY AND ONCOLOGY |
• – – |
2018-12-16 |
4 |
D |
$68.20 |
$100,731 |
D/D |
(1,477) |
11,561 |
0 |
- |
|
| CELG |
Celgene Corp |
PRES., HEMATOLOGY AND ONCOLOGY |
• – – |
2018-12-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,000 |
13,038 |
0 |
- |
|
23 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
